Hepatitis Monthly

Published by: Kowsar

Interferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-Analysis

Qin Wu 1 , Cong Wang 2 , En Qiang Chen 1 , Hong Tang 1 , Zhen Zhen Li 3 and Xue Zhong Lei 1 , *
Authors Information
1 Department of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China
2 Department of Nursing, West China Hospital, Sichuan University, Chengdu, China
3 West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
Article information
  • Hepatitis Monthly: December 01, 2015, 15 (12); e32707
  • Published Online: December 19, 2015
  • Article Type: Review Article
  • Received: August 25, 2015
  • Revised: October 30, 2015
  • Accepted: November 1, 2015
  • DOI: 10.5812/hepatmon.32707

To Cite: Wu Q, Wang C, Chen E Q, Tang H, Li Z Z, et al. Interferon Lambda 4 Polymorphism Predicts Sustained Viral Response in Hepatitis C Virus Patients Irrespective of Hepatitis C Virus Genotypes, Ethnicity or Treatment Regimen: Results From a Meta-Analysis, Hepat Mon. 2015 ;15(12):e32707. doi: 10.5812/hepatmon.32707.

Abstract
Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Evidence Acquisition
3. Results
4. Conclusions
Footnote
References
  • 1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013; 57(4): 1333-42[DOI][PubMed]
  • 2. European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2011; 55(2): 245-64[DOI][PubMed]
  • 3. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Hepatology. 2011; 54(4): 1433-44[DOI][PubMed]
  • 4. European Association of the Study of the L. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2012; 32 Suppl 1: 2-8[DOI][PubMed]
  • 5. Jia Z, Ding Y, Tian S, Niu J, Jiang J. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: Results from a meta-analysis. PLoS One. 2012; 7(9)[DOI][PubMed]
  • 6. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2012; 36(2): 91-103[DOI][PubMed]
  • 7. Yang M, Rao HY, Feng B, Zhang W, Wei L. Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: A meta-analysis. J Gastroenterol Hepatol. 2013; 28(7): 1114-21[DOI][PubMed]
  • 8. Li S, Hu P, Zhang QQ, Liu YH, Hu HD, Zhang DZ, et al. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B. Hepat Mon. 2011; 11(3): 163-72[PubMed]
  • 9. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013; 45(2): 164-71[DOI][PubMed]
  • 10. Thong VD, Wasitthankasem R, Tangkijvanich P, Vongpunsawad S, Poovorawan Y. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection. PLoS One. 2015; 10(5)[DOI][PubMed]
  • 11. Franco S, Aparicio E, Parera M, Clotet B, Tural C, Martinez MA. IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients. AIDS. 2014; 28(1): 133-6[DOI][PubMed]
  • 12. Akkarathamrongsin S, Thong VD, Payungporn S, Poovorawan K, Prapunwattana P, Poovorawan Y, et al. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. J Med Virol. 2014; 86(9): 1482-90[DOI][PubMed]
  • 13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9): 603-5[DOI][PubMed]
  • 14. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. 2008;
  • 15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-88[DOI]
  • 16. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4): 719-48[PubMed]
  • 17. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988; 7(8): 889-94[PubMed]
  • 18. O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, et al. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol. 2015; 63(5): 1103-10[DOI][PubMed]
  • 19. Fujino H, Imamura M, Nagaoki Y, Kawakami Y, Abe H, Hayes CN, et al. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J Gastroenterol. 2014; 49(12): 1548-56[DOI][PubMed]
  • 20. Nagaoki Y, Imamura M, Kawakami Y, Kan H, Fujino H, Fukuhara T, et al. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. Hepatol Res. 2014; 44(14)-54[DOI][PubMed]
  • 21. Stattermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, et al. Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014; 39(1): 104-11[DOI][PubMed]
  • 22. Holmes JA, Congiu M, Bonanzinga S, Sandhu MK, Kia YH, Bell SJ, et al. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3. Aliment Pharmacol Ther. 2015; 42(3): 296-306[DOI][PubMed]
  • 23. Miyamura T, Kanda T, Nakamoto S, Arai M, Nakamura M, Wu S, et al. IFNL4 ss469415590 Variant Is Associated with treatment response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens. Int J Hepatol. 2014; 2014: 723868[DOI][PubMed]
  • 24. Palmieri O, Ippolito AM, Margaglione M, Valvano MR, Gioffreda D, Fasano M, et al. Variation in genes encoding for interferon lambda-3 and lambda-4 in the prediction of HCV-1 treatment-induced viral clearance. Liver Int. 2014; 34(9): 1369-77[DOI][PubMed]
  • 25. Susser S, Herrmann E, Lange C, Hamdi N, Muller T, Berg T, et al. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One. 2014; 9(11)[DOI][PubMed]
  • 26. Covolo L, Bibert S, Donato F, Bochud PY, Lagging M, Negro F, et al. The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection. Aliment Pharmacol Ther. 2014; 39(3): 322-30[DOI][PubMed]
  • 27. Akamatsu S, Hayes CN, Tsuge M, Murakami E, Hiraga N, Abe H, et al. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism. J Viral Hepat. 2015; 22(2): 166-74[DOI][PubMed]
  • 28. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25): 2405-16[DOI][PubMed]
  • 29. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012; 56(1): 78-84[DOI][PubMed]
  • 30. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10): 1100-4[DOI][PubMed]
  • 31. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011; 54(3): 415-21[DOI][PubMed]
  • 32. Mi Y, Gao YT, Jiao XL, Guo H, Liu T, Jing L, et al. The role of interleukin-28b gene polymorphisms in chinese patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Hepat Mon. 2014; 14(8)[DOI][PubMed]
  • 33. Wu Q, Zhan FY, Chen EQ, Wang C, Li ZZ, Lei XZ. predictors of pegylated interferon alpha and ribavirin efficacy and long-term Assessment of relapse in patients with chronic hepatitis C: A one-center experience from China. Hepat Mon. 2015; 15(6)[DOI][PubMed]
  • 34. Meissner EG, Bon D, Prokunina-Olsson L, Tang W, Masur H, O'Brien TR, et al. IFNL4-DeltaG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J Infect Dis. 2014; 209(11): 1700-4[DOI][PubMed]
  • 35. Fernandez-Carrillo C, Coto-Llerena M, Gonzalez P, Crespo G, Mensa L, Caro-Perez N, et al. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. J Clin Virol. 2014; 61(2): 282-5[DOI][PubMed]
  • 36. Watanabe S, Kobayashi Y, Kawata K, Noritake H, Chida T, Nagasawa M, et al. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders. Intern Med. 2015; 54(3): 273-9[DOI][PubMed]
  • 37. Sandoughdaran S, Alavian SM, Sharafi H, Behnava B, Salimi S, Mehrnoush L, et al. Efficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy. Hepat Mon. 2015; 15(1)[DOI][PubMed]
  • 38. Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013; 37(10): 921-36[DOI][PubMed]
  • 39. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13): 1207-17[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments